Question 1

Has Philip Imus, MD received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $583,570 in general payments to Philip Imus, MD across 41 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Philip Imus, MD did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Philip Imus, MD come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Janssen Research & Development, LLC	38	$575,069
National Marrow Donor Program	3	$8,501

Drug	Claims	Cost to plans & patients
RevlimidLenalidomide	178	$3,096,665
PomalystPomalidomide	136	$2,863,999
Lenalidomide	42	$592,656
VenclextaVenetoclax	21	$538,991
BrukinsaZanubrutinib	11	$160,710
EliquisApixaban	22	$14,987
Acyclovir	51	$1,385
ValacyclovirValacyclovir Hcl	13	$1,049
Dexamethasone	49	$933
Potassium Chloride	14	$532
Gabapentin	15	$523
Oxycodone Hcl	20	$266
Prochlorperazine Maleate	14	$175
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	16	$171
Ondansetron Hcl	12	$61

Philip Imus, MD

Payments from drug & device makers

Who reported the general payments

How this compares

Medicare billing

Most prescribed under Part D

Other medical oncology in Baltimore